Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2023.08.21

Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various stages of clinical development.

Marking the entry into its 25th year, the Chairman Dr. K. Ranga Raju and members of the senior management inaugurated multiple new laboratories and facilities, and a grand new entrance to its 12-acre integrated R&D campus in Hyderabad. Notable among the new laboratories were a doubling of its DMPK footprint and a sizeable expansion of analytical R&D capacity for its Discovery Chemistry services.

Expressing delight on the occasion, Dr. K. Ranga Raju, Founder Chairman, said, “Over the last 24 years, thanks to the trust that our clients have reposed in us, Sai Life Sciences has grown from a small lab with two fume hoods into a global CRO-CDMO providing the entire range of services along the drug discovery journey with world-class facilities across three continents and propelled by a 2,900-strong talent pool. As we look to the future, we rededicate ourselves to working with global innovator partners to accelerate a healthier future.”

The occasion also formally concluded the company’s Sai Nxt initiative, which witnessed strategic investments of over US$130 million during 2019-2023, enabling the company to augment capacity, scale up operations, expand into new geographies, grow the scientific talent base, and raise the overall bar for quality, compliance, and performance.

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “In 2016, we set a vision for ourselves to support our global innovator partners in bringing 25 new medicines to life by 2025. I’m delighted to share that we’ve surpassed this goal two years ahead of schedule. There can’t be anything more gratifying for us as a company as we enter our silver jubilee year.”

The company has announced a series of initiatives as part of its 25th year celebrations culminating in August 2024, to commemorate the company’s journey, acknowledge contributions of various individuals, and engage all its stakeholders in charting a collective future.

Sauri Gudlavalleti, Chief Operating Officer said, “We are excited about the next phase of our growth. We will actively engage with our clients, partners, and employees to chart a journey that will enable us to meaningfully impact the future of healthcare.”

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more